Effect of Bacille‐Calmette‐Guerin vaccine against rotenone‐induced Parkinson's disease: Role of neuroinflammation and neurotransmitters
Fundamental & Clinical Pharmacology · 2024-06 · 38 (3) · 538-549
DOI: 10.1111/fcp.12968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 02.12.2023. Verfasst von Narhari Gangaram Yedke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, India. Hauptthemen laut MEDLINE: Rotenone, Neuroprotective Agents, Neuroinflammatory Diseases, Neurotransmitter Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Government of India, New Delhi.
Abstract (Originalsprache)
Background
Parkinson's disease (PD) is an extrapyramidal movement disorder associated with a hypokinetic condition generated by impairment in dopaminergic neuronal viability in the nigrostriatal region of the brain. Current medications can only provide symptomatic management; to date, no permanent cure is available. To compensate for this lacuna, researchers are gaining interest in antigen‐based therapy, and Bacille‐Calmette‐Guerin (BCG) is one of the vaccines with a high safety margin that acts by stimulating immunoreactive T‐cells in the CNS and reducing expression of pro‐inflammatory cytokines including interleukin (IL)‐1β and tumor necrotic factor (TNF‐α) to produce neuroprotection. A previous study reported that BCG exerts a neuroprotective effect against several neurodegenerative disorders, such as Alzheimer's disease.
Objective
The objective of this study is to explore the neuroprotective effect of the BCG vaccine against the rotenone model of PD.
Methods
Rotenone (1.5 mg/kg, s.c ) for 28 days, and BCG vaccine (2 × 10 7 cfu, i.p ) single dose was injected to rats, and behavioral assessments were performed on the 21st and 28th day. On the 29th day, rats were sacrificed, and brains were isolated for biochemical and neurochemical estimation.
Results
BCG vaccine significantly restored rotenone‐induced motor deficits (open field test, narrow beam walk, and rotarod), biochemical levels (GSH, SOD, catalase, MDA, and nitrite), neurotransmitters (dopamine, 5‐hydroxy tryptamine, norepinephrine, 3,4‐dihydroxyphenylacetic acid, hemovanillic acid, and 5‐hydroxy indoleacetic acid), and levels of inflammatory cytokines (IL‐1β and TNF‐α) in the striatum. It also prevents histopathological changes by reducing eosinophilic lesions in the striatum.
Conclusion
From the results, we conclude that BCG vaccine showed neuroprotection through antioxidant and anti‐inflammatory effect. Thus, in the future, it can be used as a neuroprotective agent for other neurological disorders, including PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, India.
- Department of Pharmacology, Central University of Punjab, Bathinda, India.
ORCID-Profile: Puneet Kumar
Förderung
- Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Government of India, New Delhi
Zitieren
APA
Yedke, N. G., Soni, D., & Kumar, P. (2024). Effect of Bacille‐Calmette‐Guerin vaccine against rotenone‐induced Parkinson's disease: Role of neuroinflammation and neurotransmitters. Fundamental & Clinical Pharmacology, 38(3), 538-549. https://doi.org/10.1111/fcp.12968
Vancouver
Yedke NG, Soni D, Kumar P. Effect of Bacille‐Calmette‐Guerin vaccine against rotenone‐induced Parkinson's disease: Role of neuroinflammation and neurotransmitters. Fundamental & Clinical Pharmacology. 2024;38(3):538-549. doi:10.1111/fcp.12968
BibTeX
@article{Yedke2024,
author = {Yedke, Narhari Gangaram and Soni, Divya and Kumar, Puneet},
title = {Effect of Bacille‐Calmette‐Guerin vaccine against rotenone‐induced Parkinson's disease: Role of neuroinflammation and neurotransmitters},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
volume = {38},
number = {3},
pages = {538--549},
doi = {10.1111/fcp.12968}
}
EUVIMED